The efficiency of anti-EGFR depends on the KRAS/BRAF mutation status, as it was demonstrated that BRAF-mutated tumours had reduced response rates to anti-EGFR, even though they were KRAS wild-type [31]. Here, EGFR is linked to neoplasm.